Join our daily newsletter At The Bell to receive exclusive market insights
- Invion’s (IVX) Photosoft compound demonstrates more than 99 per cent inhibition against the Zika virus when exposed to specific light wavelengths
- The results come from in vitro studies that were carried out by leading contract research and clinical lab service company, Viroclinics-DDL and Virology Research Services
- The studies showed selected Photosoft compounds were effective against the virus and were more effective than the antibiotic Monensin which is known to be effective against Zika in in vitro lab tests
- Photosoft is being developed as a novel next-generation photodynamic therapy which use non-toxic photosensitisers and light to selectively kill cancer cells
- Shares in Invion are trading steady at 1.3 cents at 2:23 pm AEST
Invion’s (IVX) Photosoft compound has demonstrated more than 99 per cent inhibition against the Zika virus when exposed to specific light wavelengths.
The results come from in vitro studies that were carried out by leading contract research and clinical laboratory service company, Viroclinics-DDL and Virology Research Services.
The studies showed selected Photosoft compounds were effective against the virus and were more effective than the antibiotic Monensin which is known to be effective against Zika in in vitro lab tests.
Photosoft is being developed as a novel next-generation photodynamic therapy (PDT).
PDTs use non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response.
“This is the first set of studies we have undertaken using Photosoft compounds on infectious diseases and we are very excited by not only the positive results, but by the potential for the technology in an era where the next global pandemic could be lurking around the corner,” Chairman and CEO Thian Chew said.
“With the continued emergence of new viral diseases in recent years, it is important that
companies like Invion continue to focus on developing new innovative treatments. We are
also exploring other viral indications to determine the potential for other viruses of interest.”
Shares in Invion were trading steady at 1.3 cents at 2:23 pm AEST.
